10069479New AI-based method for early detection of lung cancerClosedEU-FundedHorizon Europe GuaranteeSierra Medical (SM) is developing SM-S1 - a highly innovative early-stage lung cancer (LC) detection test which combines artificial intelligence (AI) and the biochemistry of a patient's cheek cells. Our novel analytical algorithm combines infrared spectroscopy, biological/medical information, machine learning and AI to extract subtle spectral differences between healthy and diseased cells (Slide 5). Our system is non-destructive (tests can be performed on the same sample), requires only a few hundred cells and is easy-to-use by any healthcare professionals without extensive training. It could be easily conducted at home or in a Primary Care setting (GP practice or pharmacy). Our first product, SM-S1, is a LC early detection tool that uses only a cheek swab, and our latest clinical trial results are very promising, showing sensitivity of 93%. Also, our technology and software platforms are being developed to detect other diseases, such as oesophageal and colon cancers, and analyse other sample types, as biopsy tissue samples.